Physician profile
David G Browning
NPI 1073948683
$10,572.05
in general payments reported to CMS, 2019-2025
23 companies · $668 in 2025
The $668 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,772 · 2022: $3,844 · 2023: $683 · 2024: $604 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,727 · Education: $229.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,726.62 |
| Education | $228.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $6,938.31 | 2021-2024 | Otezla |
| Abbvie INC. | $754.99 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $499.69 | 2021-2025 | |
| Janssen Biotech, INC. | $318.19 | 2021-2025 | Tremfya |
| Leo Pharma INC. | $272.53 | 2021-2025 | Adbry, Anzupgo |
| Sun Pharmaceutical Industries INC. | $214.96 | 2021-2025 | Absorica Ld, Winlevi |
| E.R. Squibb & Sons, L.L.C. | $185.02 | 2022-2025 | Sotyktu |
| Galderma Laboratories, L.P. | $173.76 | 2021-2025 | Aklief |
| Incyte Corporation | $150.29 | 2021-2022 | |
| Biofrontera INC. | $141.89 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Regeneron Healthcare Solutions, INC. | $140.39 | 2021-2023 | Dupixent |
| Genzyme Corporation | $131.31 | 2021-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $124.23 | 2021-2025 | Cabtreo, Jublia |
| Pfizer INC. | $119.86 | 2021-2022 | |
| Regeneron Pharmaceuticals, INC. | $71.43 | 2021-2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vyne Pharmaceuticals INC. | $55.53 | 2021 | |
| Lilly USA, LLC | $54.74 | 2021-2024 | Olumiant, Ebglyss, Taltz |
| Helsinn Therapeutics (U.S.), INC. | $53.97 | 2021-2023 | Valchlor |
| Allergan, INC. | $47.54 | 2021 | |
| Arcutis Biotherapeutics, INC. | $42.39 | 2023 | |
| Organon LLC | $38.83 | 2025 | Vtama |
| Almirall LLC | $25.45 | 2025 | Seysara |
| Dermavant Sciences, INC. | $16.75 | 2024 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Browning listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.